<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862170</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.255</article-id><article-id pub-id-type="other">EPP0016</article-id><article-id pub-id-type="pii">S0924933824002554</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Clinical suitability of intranasal delivery of M2 macrophage soluble factors in patients with post-COVID olfactory disorders</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Markova</surname><given-names>E.</given-names></name><xref rid="aff0444" ref-type="aff">
<sup>1</sup></xref><xref rid="cor0116" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Shevela</surname><given-names>E.</given-names></name><xref rid="aff0444" ref-type="aff">
<sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Davydova</surname><given-names>M.</given-names></name><xref rid="aff0444" ref-type="aff">
<sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Meledina</surname><given-names>I.</given-names></name><xref rid="aff0444" ref-type="aff">
<sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ostanin</surname><given-names>A.</given-names></name><xref rid="aff0444" ref-type="aff">
<sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kozlov</surname><given-names>V.</given-names></name><xref rid="aff0444" ref-type="aff">
<sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chernykh</surname><given-names>E.</given-names></name><xref rid="aff0444" ref-type="aff">
<sup>1</sup></xref></contrib></contrib-group><aff id="aff0444">
<sup>1</sup><institution>State Research Institute of Fundamental and Clinical Immunology</institution>, <city>Novosibirsk</city>, <country>Russian Federation</country></aff><author-notes><corresp id="cor0116"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="230">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S105</fpage><lpage>S105</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824002554a.pdf"/><abstract><sec id="sec0695"><title>Introduction</title><p>SARS-CoV virus showed transneuronal penetration through the olfactory bulb resulting in the rapid intracranial spread.&#x000a0;So, olfactory dysfunction is an early marker of COVID-19 infection. However, individuals may develop chronic olfactory impairment for more than six months in 1&#x02013;10% of cases.</p></sec><sec id="sec0696"><title>Objectives</title><p>The study&#x02019;s objective was to evaluate the efficacy and safety of intranasal immunotherapy using bioactive substances produced by M2 macrophages for the treatment of people with long-term post-COVID-19 hyposmia.</p></sec><sec id="sec0697"><title>Methods</title><p>Seven individuals with long-term persistent hyposmia (7 to 24 months), associated with PCR-confirmed coronavirus infection were evaluated for olfactory function at baseline, one, and six to twelve months after therapy.</p></sec><sec id="sec0698"><title>Results</title><p>The intranasal inhalation of M2 macrophage conditioned medium (one time per day for 28-30 days) was well tolerated. Furthermore, olfactometry demonstrated that the patients restored their capacity to perceive (Kruskal-Wallis H test 14.123, p = 0.0009) and recognize odors (H = 11.674, p = 0.0029). In addition, the subjective evaluation of smell significantly improved (H = 11.935, p = 0.0026). At the 6-
to 12-month follow-up, the majority of patients (5/7) reported extremely high levels of satisfaction with the outcomes, and the remaining two patients also felt generally positive about the therapy&#x02019;s success.</p></sec><sec id="sec0699"><title>Conclusions</title><p>Overall, our study showed that the use of intranasal inhalations as a method of delivering bioactive factors and the conditioned medium of M2 macrophages as a therapeutic agent are both safe, well tolerated and, according to preliminary data, clinically effective in the treatment of patients with long-term post-COVID-19 hyposmia.</p></sec><sec id="sec0700"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>